Core Insights - Argenx SE will present data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting, highlighting advancements in treatments for severe autoimmune diseases [1][2] Group 1: VYVGART Developments - New Phase 3 results in ocular myasthenia gravis (oMG) will demonstrate VYVGART's potential as a targeted treatment option for patients [2][5] - Positive results from the Phase 3 ADAPT OCULUS study confirm VYVGART's therapeutic potential in adults with oMG, marking a significant advancement in treatment options [6] - Data from the ADAPT SERON study supports VYVGART's efficacy across broader patient populations, including generalized myasthenia gravis (gMG) patients without detectable anti-acetylcholine receptor antibodies [6][39] Group 2: Pipeline Candidates - Argenx will share results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes, showing a favorable safety profile and functional improvements [4][39] - Empasiprubart, a novel monoclonal antibody, is being evaluated for multiple severe autoimmune indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) [29] Group 3: CIDP Insights - Results from an ADHERE post hoc analysis will highlight VYVGART Hytrulo's impact in treatment-naïve CIDP patients, supporting its earlier use in treatment paradigms [3][39] - Real-world insights will illustrate physician approaches to transitioning patients from intravenous immunoglobulin to VYVGART Hytrulo, aiming to enhance patient outcomes [39] Group 4: Presentation Details - The presentations at the AAN Annual Meeting will include various studies on myasthenia gravis and CIDP, showcasing the breadth of research and data supporting VYVGART and its pipeline candidates [4][6][7]

Summary of Argenx Conference Call Company Overview - **Company**: Argenx - **Event**: 46th Annual TD Cowen Healthcare Conference - **New CEO**: Karen Massey Key Points and Arguments Vision and Strategic Focus - Argenx 2.0 is a growth story focused on innovation, aiming to reach 50,000 patients by the end of the decade with 10 labeled indications and 5 molecules in late-stage development [4][5] - Short-term growth is expected from upcoming readouts in myositis and VYVGART for MMN, with plans for Sjögren's and CIDP in the future [5][6] Product Pipeline and Development - The FcRn strategy includes two next-generation molecules and an oral formulation, expanding the pipeline beyond FcRn [5][6] - Early-stage programs are being developed, including a recent deal with Tensegrity [6] VYVGART Performance - VYVGART has shown strong year-on-year growth, with a PDUFA date in May for seronegative MG patients and positive ocular MG data [23][24] - The company has reached $1 billion in sales, with CIDP accounting for approximately 35% of sales [26][27] - VYVGART is positioned as the number one prescribed biologic in MG, with a focus on removing friction for prescribers regarding antibody status [28][29] Market Dynamics and Competition - The company is aware of competition but believes VYVGART's safety profile and efficacy position it well against alternatives [59] - The market for MG treatments is evolving, with FcRns being used as first-line therapies, while C5 therapies are reserved for refractory patients [32][35] Myositis and Clinical Trials - The myositis trial is designed to assess efficacy across multiple subtypes, allowing flexibility in approval based on data [67][68] - The prevalence of DM and MMN is highlighted, with a focus on the unmet need in IMN [73][74] Sjögren's and Future Studies - The company is optimistic about the Sjögren's program, with plans for additional evidence generation following positive readouts [90][91] EMPA and CIDP Strategy - EMPA is positioned to transform outcomes for CIDP patients, with a focus on biomarker data and understanding patient heterogeneity [115][116] - The company is also exploring combination studies in MG, indicating a broad strategy for future indications [118][120] IgA Sweeper Development - The IgA sweeper is being developed for IgA nephropathy (IgAN) with plans for further indications like IgA vasculitis [124][129] Additional Important Insights - The company emphasizes the importance of treating ocular MG, as it significantly impacts patients' quality of life [51][52] - The competitive landscape is acknowledged, with a focus on differentiating VYVGART through its unique dosing options and safety profile [59][60] This summary encapsulates the key discussions and strategic directions presented during the conference call, highlighting Argenx's commitment to innovation and growth in the biotech sector.

Core Insights - Zai Lab is advancing its global oncology pipeline with a focus on zoci, a DLL3-targeting antibody-drug conjugate, which is in a global registrational Phase III study for small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs) [2][6][3] - The company anticipates an accelerated approval submission for zoci in 2027 and a first global approval in 2028, with promising clinical activity demonstrated in patients with brain metastases [1][6][3] - Zai Lab's commercially profitable business in China is funding its global R&D efforts, with fourth-quarter revenue increasing by 17% year-over-year to $127.6 million and a full-year revenue of $460 million [5][14] Pipeline Development - Zai Lab has initiated a global registrational Phase III study for zoci, targeting approximately 480 patients, with enrollment expected to reach 75% by the end of 2026 [2][6] - Additional pipeline developments include ZL-6201, which has received U.S. IND clearance and is entering a global Phase I study, and ZL-1222, which is progressing through IND-enabling studies [4][8] - The company is also advancing ZL-1503 for atopic dermatitis and plans to present initial data for NECs in the first half of 2026 [9][10] Financial Performance - Zai Lab reported a 19% improvement in operating loss to $229.4 million for the full year, with cash reserves of $790 million as it aims for corporate cash-flow breakeven [5][21] - R&D expenses decreased by 6% year-over-year, while SG&A expenses also saw a reduction, contributing to improved financial leverage [20][21] - The company expects a more measured growth profile in 2026, influenced by pricing dynamics and competition, while maintaining a long-term growth trajectory supported by guideline expansions [15][22] Strategic Focus - Zai Lab is focusing on building a globally innovative company, leveraging its China business for stability and funding [3] - The company is exploring first-line SCLC combination strategies and strengthening its oncology platform through targeted collaborations [13] - Zai Lab plans to initiate the commercial launch of KarXT in the second quarter of 2026, emphasizing disease awareness and clinical confidence [17]

FDA Approvals & Rejections - Armata Pharmaceuticals received FDA QIDP designation for AP-SA02, a bacteriophage-based candidate for complicated Staphylococcus aureus bacteremia, providing five years of market exclusivity and eligibility for Fast Track status [2][3] - Allurion Technologies gained FDA PMA approval for the Gastric Balloon System, a swallowable Smart Capsule that promotes fullness for about four months, targeting patients with a BMI of 30-40 [4][5] - Eton Pharmaceuticals' DESMODA oral solution was approved for managing central diabetes insipidus, with an expected peak annual sales of $30 million - $50 million [9][11] Deals - Gilead Sciences announced the acquisition of Arcellx for $115 per share, totaling an implied equity value of $7.8 billion, enhancing its position in cell therapy [12][13] - Vir Biotechnology entered a global collaboration with Astellas for VIR-5500, receiving $335 million in upfront payments and potential additional milestones of up to $1.37 billion [14][15][16] - Kairos Pharma signed a term sheet to acquire two oncology assets from Celyn Therapeutics, focusing on cancer therapeutics [17][18][20] Clinical Trials - Breakthroughs - MoonLake Immunotherapeutics reported positive Phase 2 trial results for Sonelokimab in axial spondyloarthritis, with 81% of patients achieving an ASAS40 response at Week 12 [21][22] - Novo Nordisk's CagriSema missed its primary endpoint in a Phase 3 trial against Zepbound, showing 23% weight loss compared to 25.5% with Tirzepatide [25][26][27] - Gossamer Bio's seralutinib missed the primary endpoint in the PROSERA Phase 3 study for pulmonary arterial hypertension, showing a placebo-adjusted improvement in Six-Minute Walk Distance [28][30][31] - Argenx's VYVGART met primary goals in the Phase 3 ADAPT OCULUS trial for ocular myasthenia gravis, demonstrating significant improvement in ocular scores [37][38][39]

Core Insights - Argenx SE reported strong fourth-quarter results, with earnings of $8.02 per share, exceeding the consensus estimate of $6.02, and sales increased from $761.2 million to $1.32 billion, surpassing the consensus estimate of $1.29 billion [1] - The company announced positive topline results from the Phase 3 ADAPT OCULUS study for VYVGART in adults with ocular myasthenia gravis [1] Financial Performance - Fourth-quarter earnings per share were $8.02, beating expectations [1] - Sales rose significantly from $761.2 million to $1.32 billion, exceeding analyst estimates [1] Product Development and Market Impact - VYVGART reached 19,000 patients globally, indicating successful market penetration [2] - The company expanded its impact in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) through the launch of a pre-filled syringe [2] - Progress was made in advancing the development pipeline towards key milestones [2] Stock Performance - Argenx shares closed at $771.53 following the earnings announcement [2] - Analysts adjusted their price targets for Argenx after the earnings report [2]

Core Insights - Argenx SE reported strong fourth-quarter results, with earnings of $8.02 per share, exceeding the consensus estimate of $6.02, and sales increased from $761.2 million to $1.32 billion, surpassing the consensus estimate of $1.29 billion [1] - The company announced positive topline results from the Phase 3 ADAPT OCULUS study for VYVGART in adults with ocular myasthenia gravis [1] Group 1 - CEO Tim Van Hauwermeiren highlighted the achievement of reaching 19,000 patients globally with VYVGART and the successful launch of the pre-filled syringe, which expanded the company's impact across generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [2] - The company made substantial progress in its development programs, advancing its pipeline towards key milestones [2] - Following the earnings announcement, analysts adjusted their price targets for Argenx shares, which closed at $771.53 [2]

Core Insights - Zai Lab Limited reported a revenue of $127.6 million for the quarter ended December 2025, reflecting a 17% increase year-over-year and a surprise of +6.85% over the Zacks Consensus Estimate of $119.42 million [1] - The company's EPS was -$0.46, an improvement from -$0.80 in the same quarter last year, although it was a -4.55% miss compared to the consensus estimate of -$0.44 [1] Revenue Breakdown - Total Product Revenue was $127.09 million, slightly below the average estimate of $132.11 million from three analysts [4] - Revenue from XACDURO was $10.7 million, exceeding the two-analyst average estimate of $9.6 million [4] - VYVGART generated $21.9 million, significantly lower than the average estimate of $39.74 million, representing a year-over-year decline of -27% [4] - NUZYRA reported $16 million, which is a +45.5% increase compared to the year-ago quarter, but below the average estimate of $17.22 million [4] - Collaboration revenue was $0.51 million, falling short of the average estimate of $19.34 million from two analysts [4] - ZEJULA achieved $56 million in revenue, surpassing the average estimate of $49.17 million and showing a year-over-year increase of +15.7% [4] Stock Performance - Zai Lab Limited's shares have returned +12.7% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Financial Data and Key Metrics Changes - Product net sales for Q4 2025 were $1.3 billion, and for the full year, they reached $4.2 billion, representing a year-over-year growth of 90% [16][18] - Operating profit for Q4 was $367 million, and for the full year, it was $1.1 billion, marking the first year of annual operating profitability [18] - Cash balance at the end of Q4 was $4.4 billion, an increase of over $1 billion from the previous year [18] Business Line Data and Key Metrics Changes - VYVGART is leading the growth in both Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with significant patient adoption and label expansion opportunities [9][22] - The company reached 19,000 patients globally, driven by the successful launch of the prefilled syringe for self-injection [7][20] - In CIDP, the company is beginning to see expansion beyond the initial 12,000 addressable patients, with a focus on continued evidence generation and patient activation [11][39] Market Data and Key Metrics Changes - In Q4 2025, product revenue breakdown included $1.1 billion in the U.S., $63 million in Japan, $110 million in the rest of the world, and $26 million in products supplied to Zai Lab in China [16] - The U.S. product net sales grew by 68% from the fourth quarter of the prior year, reflecting solid patient demand and prescriber confidence [16] Company Strategy and Development Direction - The company aims to impact more patients globally with VYVGART through broader patient adoption and label expansion, focusing on next-generation molecules and combination approaches [8][9] - The strategic priorities for 2026 include advancing the immunology pipeline and delivering at least one new pipeline candidate per year [8][12] - The company is committed to expanding its reach into autoimmune myositis and Sjögren's disease, addressing significant unmet needs [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of VYVGART, particularly with the upcoming PDUFA date for seronegative MG and the positive results for ocular MG [31][32] - The leadership transition is seen as timely, with the company well-positioned for its next phase of growth [26][78] - Management highlighted the importance of maintaining a strong balance sheet to support ongoing investments in the commercial business and pipeline [18][96] Other Important Information - The company is advancing two next-generation assets, ARGX-213 and ARGX-124, to enhance patient experience and expand indications [12][70] - The prefilled syringe has proven to be a key driver in increasing overall VYVGART demand, with over 4,700 prescribers at the end of Q4 [20][21] Q&A Session Summary Question: On the addition of seronegative and ocular MG to the revenue stream for VYVGART - Management confirmed that VYVGART is the first and only therapy with positive data for ocular MG, positioning the company well for sustained growth in MG [31] - The addressable market for ocular MG is estimated at 7,000 patients, with ongoing market research to refine these estimates [32] Question: On the CIDP opportunity and coverage expansion - Management noted that CIDP growth is primarily from patients switching from IVIG, with recent coverage expansion to over 90% of covered lives expected to enhance adoption rates [39] Question: On the impact of ocular MG approval on less advanced MG patients - Management indicated that the ocular MG data will support the strategy to expand biologic use to earlier lines of treatment in MG [42] Question: On Q1 dynamics and growth expectations - Management acknowledged seasonal dynamics affecting Q1 performance but expressed confidence in the underlying growth drivers for the full year [49][50] Question: On VYVGART growth dynamics and competitive landscape - Management emphasized continued growth across all indications and formulations, welcoming competition as a sign of market expansion [89][90]

Financial Data and Key Metrics Changes - Product net sales for Q4 2025 were $1.3 billion, and for the full year, they reached $4.2 billion, reflecting a year-over-year growth of 90% [16] - Operating profit for Q4 was $367 million, and for the full year, it was $1.1 billion, marking the first year of annual operating profitability [18] - Cash balance at the end of Q4 was $4.4 billion, representing an increase of over $1 billion for the year [18] Business Line Data and Key Metrics Changes - VYVGART is leading the growth in both Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with significant patient adoption and label expansion opportunities [9][10] - The company reached approximately 19,000 patients globally by the end of 2025, driven by the successful launch of the prefilled syringe for self-injection [20] - In CIDP, the company is beginning to see expansion beyond the initial 12,000 addressable patients, with a focus on continued evidence generation and patient activation [39] Market Data and Key Metrics Changes - In Q4 2025, product revenue breakdown included $1.1 billion in the U.S., $63 million in Japan, $110 million in the rest of the world, and $26 million in products supplied to Zai Lab in China [16] - The U.S. product net sales grew by 68% from the fourth quarter of the prior year, reflecting solid patient demand and prescriber confidence [16] Company Strategy and Development Direction - The company aims to impact more patients globally with VYVGART through broader patient adoption and label expansion, with a goal of at least one new pipeline candidate per year [8][9] - The strategic priorities for 2026 include advancing the immunology pipeline and expanding into new patient populations, including autoimmune myositis and Sjögren's disease [11][12] - The company is committed to establishing FcRn leadership for decades to come, with investments in next-generation assets and innovative delivery modalities [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of VYVGART, particularly with the upcoming PDUFA date for seronegative MG and the positive results for ocular MG [31][32] - The company anticipates continued revenue growth exceeding operating expense growth, leading to increased operating margins over time [95] - Management highlighted the importance of maintaining a strong balance sheet to support ongoing investments in the commercial business and pipeline [18][96] Other Important Information - The company is advancing two next-generation assets, ARGX-213 and ARGX-124, to enhance patient experience and expand indications [12][70] - The prefilled syringe has proven to be a key driver in increasing overall VYVGART demand, with over 4,700 prescribers by the end of Q4 2025 [20][21] Q&A Session Summary Question: What is the expected average price for seronegative and ocular MG indications? - Management indicated that they expect a similar price to MG, approximately $225,000 net price to argenx, pending discussions with payers [34] Question: Can you elaborate on the CIDP opportunity and its expansion? - Management noted that they are beginning to see use beyond the initial 12,000 patients, with a focus on continued growth and evidence generation [39] Question: Will approval in ocular MG drive more utilization in less advanced MG patients? - Management believes that the ocular MG data will support the strategy of expanding biologic use to earlier lines of MG treatment [42] Question: What are the dynamics to consider for Q1? - Management acknowledged seasonal dynamics affecting Q1, including reverifications and winter storms, but expects continued growth based on healthy underlying dynamics [49][50] Question: How should we think about the sustainability of VYVGART's growth profile? - Management emphasized that revenue growth should exceed operating expense growth, leading to a sustainable and profitable business model [95][96]

Zai Lab (NasdaqGM:ZLAB) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristine Chiou - SVP of Investor RelationsHaichong Lin - AssociateJonathan Chang - Senior Managing Director of Emerging OncologyJosh Smiley - President and COOLi Watsek - DirectorMichael Yee - Global Head of Biotechnology ResearchRafael Amado - President and Head of Global Research and DevelopmentSamantha Du - Founder, Chairperson, and CEOYajing Qian - CFOConference Call ParticipantsAnupam Rama - Managing Direct ...